Wire · opportunities
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile as a Companion ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 September 2026 · Fusion42 review
Chugai Pharmaceutical received approval from Japan's Ministry of Health for the FoundationOne CDx Cancer Genomic Profile as a companion diagnostic to guide the use of Pfizer's lorlatinib in treating ALK fusion gene-positive non-small cell lung cancer. This expands genomic profiling support for treatment decisions and improves patient access to targeted therapies.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now offer comprehensive genomic profiling as a clinical gateway to prescribing lorlatinib for ALK-positive lung cancer in Japan. This approval opens a practical path to integrate a recognised companion diagnostic, accelerating tailored treatments for oncology patients.
◆ Coverage
1 source · 18 Sep 2026
◆ Related on Wire
◆ Topics